April 16, 2020
A Delaware federal judge on Wednesday dismissed a shareholder's proposed class action alleging Keryx Biopharmaceuticals Inc. misled the public in the lead-up to a December 2018 shareholder vote on the company's acquisition by Akebia Therapeutics Inc.
October 16, 2018
Keryx Biopharmaceuticals Inc. misled investors about the company's financial future in documents related to its $1.3 billion acquisition by Akebia Therapeutics Inc., shareholders alleged in a proposed securities class action filed in Delaware federal court on Tuesday.